CBD has shown genuine ability to kill glioblastoma cells and slow tumor growth in laboratory and animal studies, and a handful of small human studies hint at improved survival when CBD is added to standard treatment. But the clinical evidence remains thin: the largest controlled trial involved just 21 patients, and no large randomized trial has yet confirmed that CBD oil extends life for people with brain tumors. The gap between promising lab results and proven clinical benefit is wide, and understanding where the science actually stands matters for anyone weighing their options.
Why Brain Tumors Have Cannabinoid Receptors in the First Place
The human brain naturally produces compounds called endocannabinoids, and brain cells carry receptors (CB1 and CB2) that respond to them. These receptors play roles in regulating inflammation, cell growth, and blood vessel formation. What caught researchers’ attention is that glioblastoma, the most aggressive primary brain cancer, appears to dramatically alter the balance of these receptors. One study comparing glioblastoma tissue to normal brain found that CB1 receptor levels dropped by about 43% in the tumor, while CB2 receptor levels soared by 765%.
1PubMed. Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomasA separate study examining the blood vessels within glioblastoma tissue found CB2 receptors present in roughly 54% of the tumor’s endothelial cells, compared to about 45% in normal brain tissue.
2PubMed. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humansThis overexpression of CB2 receptors in tumor tissue is what first suggested cannabinoids might have a way “in” to influence glioblastoma behavior. CBD interacts with these receptors (along with several other cellular targets), which is why it caught the attention of neuro-oncology researchers rather than being just another supplement claim.
What CBD Does to Glioblastoma Cells in the Lab
When researchers expose glioblastoma cell lines to CBD in a dish, several things happen. CBD slows cell division, reduces the cells’ ability to invade surrounding tissue, and triggers programmed cell death. A study using two common glioblastoma cell lines (U87-MG and T98G) found that CBD inhibited both proliferation and invasiveness, while decreasing expression of proteins involved in tumor growth, invasion, and the formation of new blood vessels.
3PubMed Central. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effectCBD also appears to target glioblastoma stem cells, the subpopulation of tumor cells thought to drive recurrence and treatment resistance. Research found that CBD converts a protein called NF-κB, which normally promotes tumor survival, into a tumor suppressor in glioblastoma stem cells. This effect was widespread in tumors characterized by low levels of reactive oxygen species (ROS), while tumors with high ROS content were resistant to CBD-induced cell death. That distinction is important because it suggests CBD won’t work equally well against all glioblastomas, and ROS levels could serve as a biomarker for identifying which tumors are more likely to respond.
4Neuro-Oncology. Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma with defined antioxidative propertiesThese lab findings are real and reproducible. The catch is that killing cancer cells in a dish is far easier than shrinking a tumor inside a living brain. Many compounds that destroy glioblastoma cells in culture never translate into treatments that help patients.
Combining CBD with Standard Glioblastoma Treatment
Standard treatment for glioblastoma involves surgery, radiation, and the chemotherapy drug temozolomide (TMZ). Much of the CBD research has focused not on CBD alone but on whether it can make these standard treatments work better. The results from animal models are encouraging but come with caveats.
In mice with human glioblastoma tumors implanted in their brains, CBD alone did not stop tumor progression. But when combined with TMZ, it significantly extended survival. The average survival for mice treated with TMZ alone was 46 days, compared to 53 days for those receiving CBD plus TMZ. Two of eleven tumors in the combination group completely regressed. A mix of CBD and THC combined with TMZ produced similar benefits.
5PubMed Central. Cannabidiol inhibits RAD51 and sensitizes glioblastoma to temozolomide in multiple orthotopic tumor modelsThe mechanism behind this sensitization appears to involve a DNA repair protein called RAD51. CBD suppressed RAD51, making it harder for tumor cells to fix the DNA damage inflicted by TMZ. However, this effect was only observed in tumors where a specific gene (MGMT) was silenced through a process called methylation. When MGMT was active, CBD did not enhance TMZ’s effectiveness. Since roughly half of glioblastoma patients have MGMT-methylated tumors, this finding means the combination strategy may only benefit a subset of patients.
Separate research examined CBD combined with THC alongside TMZ and found synergistic reductions in the growth of glioma tumors in animal models.
6PubMed. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomideRadiation studies show a similar pattern. CBD enhanced radiation-induced death in glioblastoma cells while having minimal effects on normal brain stem cells and astrocytes, suggesting a degree of selectivity.
7PubMed Central. Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways Further work showed that adding an inhibitor of the DNA damage repair enzyme ATM kinase dramatically amplified CBD’s radiation-sensitizing effects in glioblastoma neurospheres.
8PubMed Central. Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and γ-irradiation in human glioblastoma cellsOne important note of caution: a quantitative analysis of CBD combined with DNA-damaging agents found that synergistic effects occurred only over a limited concentration range, and that at low concentrations, the combination was actually antagonistic in some cell lines, meaning CBD reduced the effectiveness of the chemotherapy drug. The study also found little therapeutic window when accounting for effects on normal neural progenitor cells.
9The Journal of Pharmacology and Experimental Therapeutics. Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in CultureThe takeaway from the preclinical combination data is that CBD can boost standard treatments in certain contexts, but dose, tumor genetics, and treatment timing all matter. Getting any of those variables wrong could reduce or eliminate the benefit.
The Human Evidence So Far
This is where people understandably want to jump ahead, and it’s where the evidence gets thinnest. Only two published studies have examined CBD in glioblastoma patients, and both are small.
A retrospective review followed 15 consecutive patients with confirmed glioblastoma who received CBD at 400 to 600 milligrams per day alongside standard surgery, radiation, and chemotherapy. Of those 15, seven (about 47%) survived at least 24 months, and four (about 27%) survived at least 36 months. The mean overall survival was 24.2 months with a median of 21 months.
10PubMed Central. Cannabidiol Îœay Prolong Survival in Patients With Glioblastoma Multiforme For context, median survival for glioblastoma patients on standard treatment is typically around 14 to 16 months, so these numbers look promising. But a retrospective case series without a control group cannot prove that CBD caused the improvement. Patient selection, general health, tumor characteristics, and the quality of surgical resection all influence survival and could account for the difference.
The strongest piece of human evidence is a small randomized, double-blind, placebo-controlled trial. In this study, 21 patients with recurrent glioblastoma received either a 1:1 CBD-to-THC spray or placebo alongside dose-intense TMZ. The median survival in the CBD/THC group was over 550 days, compared to 369 days in the placebo group. One-year survival was 83% in the treatment group versus 56% on placebo, a statistically significant difference. Progression-free survival at six months was 42% versus 33%, though this difference was not statistically significant.
11Journal of Clinical Oncology. A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM)There were no severe (Grade 3 or 4) toxicities reported in the safety phase. The most common side effects were dizziness and nausea. These results are genuinely encouraging, but 21 patients is a very small sample, and the study used a CBD/THC combination rather than CBD alone. Larger trials are needed before this treatment can be considered proven.
The Blood-Brain Barrier Problem
Even if CBD works against glioblastoma in principle, getting enough of it to the tumor is a separate engineering challenge. CBD taken orally has low bioavailability — much of it is broken down by the liver before reaching the bloodstream — and the blood-brain barrier further limits how much crosses into brain tissue. This means the concentrations that kill glioblastoma cells in a dish may not be achievable in a patient’s brain through a capsule or oil dropper.
Researchers are exploring multiple strategies to solve this. Nanotechnology-based carriers designed to cross the blood-brain barrier and deliver CBD directly to glioma cells are a major area of development.
12PubMed. Improving the Biopharmaceutical Properties of Cannabinoids in Glioblastoma Multiforme Therapy With Nanotechnology: A Drug Delivery Perspective One approach used a dual-receptor-targeting nanoparticle loaded with both CBD and another anti-glioblastoma drug. The surface of the particle was coated with a peptide that helped it cross the blood-brain barrier, and interestingly, CBD itself appeared to further promote barrier penetration. In tumor-bearing mice, this system achieved a 10-fold increase in brain drug accumulation, reduced tumor burden substantially, and prolonged survival.
13Chemical Engineering Journal. A dual receptor targeting and blood–brain barrier penetrating co-drug-loaded particle mediating inhibition of oxidative phosphorylation for targeted therapy of glioblastomaInhaled CBD is another avenue being investigated. An animal study using inhaled CBD found that it limited tumor growth and altered the tumor microenvironment, suppressing markers associated with immune evasion while boosting immune responses against the tumor, including increased CD8 immune cell activity within the tumor.
14PubMed Central. Inhalant Cannabidiol Inhibits Glioblastoma Progression Through Regulation of Tumor MicroenvironmentThese delivery innovations are still in the laboratory or early preclinical stages. But they highlight a practical point for patients considering over-the-counter CBD oil: the product on a dispensary shelf was not designed to deliver therapeutic concentrations to a brain tumor, and the dose reaching the tumor is almost certainly far lower than what is used in published cell and animal studies.
Safety, Side Effects, and Drug Interactions
CBD has a reputation for being well-tolerated, and it generally is. In the clinical trial described earlier, the most common side effects were dizziness and nausea. But there are meaningful concerns that go beyond side effects, particularly around drug interactions.
CBD is metabolized by the same liver enzyme system (cytochrome P450) that processes many chemotherapy drugs, antiepileptic medications, and steroids commonly used by brain tumor patients. This means CBD can alter blood levels of other drugs in unpredictable ways, potentially increasing toxicity or reducing effectiveness of those treatments. A review examining the pharmacological interactions between CBD and standard chemotherapy drugs highlighted that while preclinical research suggests CBD could attenuate chemotherapy side effects or enhance drug efficacy, it is also a biologically active substance that modulates various cellular targets and could produce unpredictable outcomes when combined with other medications.
15PubMed Central. Drug-Drug Interactions of Cannabidiol with Standard-of-Care ChemotherapeuticsA systematic scoping review of adverse events from cannabis-based products in cancer patients, covering 152 studies, found that the most frequently reported problems involved the nervous system, psychiatric effects, and gastrointestinal symptoms.
16Springer Link / Support Care Cancer. Adverse events associated with the use of cannabis-based products in people living with cancer: a systematic scoping review For someone already dealing with the neurological effects of a brain tumor and the side effects of chemotherapy and steroids, adding another compound that affects the nervous system and interacts with their other medications is not a trivial decision. Anyone considering CBD alongside active cancer treatment should discuss it with their oncology team, not because CBD is dangerous in isolation but because the interaction landscape is complex.
Symptom Relief Beyond Tumor Control
For many brain tumor patients, the appeal of CBD is not about shrinking the tumor but about managing the symptoms and side effects that erode quality of life. Published and clinical evidence suggests cannabinoids may help with chemotherapy-induced nausea and vomiting, appetite stimulation, pain, and seizures.
17PubMed Central. Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis)Seizures are a particularly relevant concern. Brain tumors frequently cause epilepsy that is difficult to control with standard antiseizure medications. A pilot case series of three patients with brain tumor-related epilepsy who were given CBD found that two experienced reductions in seizure frequency and all three showed improvements in seizure severity scores.
18PubMed. The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy Three patients is not enough to draw firm conclusions, but CBD is already an FDA-approved treatment for certain forms of severe childhood epilepsy, so its antiseizure properties are well-established outside the brain tumor context. The question is how well those properties translate when the seizures are caused by a tumor rather than a genetic condition.
For patients whose disease has progressed beyond curative treatment, the palliative benefits of CBD may matter more than any speculative antitumor effect. Reducing nausea, improving sleep, and controlling seizures are concrete quality-of-life improvements, even if the tumor itself is unaffected.
How Patients Are Already Using It
Regardless of what the clinical evidence says, many glioma patients are already using cannabis products. A survey of glioma patients treated at a comprehensive cancer center in Florida found that over 70% had considered using medical marijuana, and a third reported using marijuana products after their diagnosis. Most of those who used it received the recommendation from friends or family rather than a medical provider, and only half had obtained a physician’s recommendation.
19PubMed Central. Medical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in FloridaThis gap between patient behavior and clinical guidance creates real risks. Patients self-dosing CBD oil from a dispensary are using a product with variable CBD content, uncertain bioavailability, and no standardized formulation. The doses used in the published clinical work (400 to 600 milligrams per day in the retrospective series, for instance) are far higher than what most over-the-counter products are designed to deliver and come at a significant cost. More concerning, patients using CBD without informing their treatment team may be unknowingly affecting the metabolism of their chemotherapy drugs or steroids.
Users in the Florida survey generally reported benefits, which is consistent with the palliative effects discussed above. But perceived benefit from a self-selected, unblinded group is the lowest tier of evidence. People who try CBD and feel nothing are less likely to keep using it and less likely to show up in a survey of users.
Why Predicting Response May Be the Key Challenge
One theme that runs through the research is variability. CBD doesn’t affect all glioblastomas equally, and the factors that determine response are only starting to be understood. Two have emerged from the preclinical work so far.
The first is MGMT methylation status. As noted in the combination studies, CBD’s ability to sensitize tumors to TMZ appears to depend on whether the MGMT gene is silenced. This is already a biomarker used in clinical practice to guide treatment decisions, so testing for it is routine. The second is the tumor’s internal level of reactive oxygen species. Research on glioblastoma stem cells found that tumors with low ROS were broadly sensitive to CBD, while those with high ROS were resistant.
20Neuro-Oncology. Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma with defined antioxidative propertiesNeither of these biomarkers has been validated in clinical trials for predicting CBD response in patients. But their existence in the lab data suggests that future trials should stratify patients by these characteristics rather than testing CBD in all comers. A trial that lumps together tumors that are biologically predisposed to respond with those that are resistant will dilute the signal. This kind of precision approach could explain why earlier, unstratified studies might underestimate CBD’s potential in the right subset of patients, or overestimate it in the wrong ones.
The Immune System Angle
Glioblastoma is notorious for suppressing local immune responses. The tumor creates an environment around itself that prevents the immune system from recognizing and attacking cancer cells. Recent research suggests CBD may push back against this immune suppression, which is a distinct mechanism from the direct tumor-killing effects described earlier.
In an animal study using inhaled CBD, the compound limited tumor growth while reshaping the immune landscape within and around the tumor. CBD suppressed several molecules that tumors use to evade immune detection, including a key immune checkpoint enzyme. At the same time, it enhanced markers associated with antigen presentation, meaning the immune system was better able to recognize the tumor, and it promoted the activity of CD8 cells, the immune cells most directly responsible for killing cancer cells.
21PubMed Central. Inhalant Cannabidiol Inhibits Glioblastoma Progression Through Regulation of Tumor MicroenvironmentThis is a single animal study, and immune effects in mice do not automatically translate to humans. But the finding is interesting because it opens a potential connection between CBD and immunotherapy, an area of active investigation in glioblastoma that has so far been disappointing with checkpoint inhibitors alone. Whether CBD could prime the tumor microenvironment to respond better to immunotherapy is a question that no one has yet tested in patients, but it represents one of the more intriguing directions the field could go.